The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
The p53 Tumor Suppressor Gene: From Molecular Biology to Clinical Investigation
Abstract
A bstract: The tumor suppressor p53 is a phosphoprotein barely detectable in the nucleus of normal cells. Upon cellular stress, particularly that induced by DNA damage, p53 can arrest cell cycle progression, thus allowing the DNA to be repaired; or it can lead to apoptosis. These functions are achieved, in part, by the transactivational properties of p53, which activate a series of genes involved in cell cycle regulation. In cancer cells bearing a mutant p53, this protein is no longer able to control cell proliferation, resulting in inefficient DNA repair and the emergence of genetically unstable cells. The most common changes of p53 in human cancers are point missense mutations within the coding sequences of the gene. Such mutations are found in all major histogenetic groups, including cancers of the colon (60%), stomach (60%), breast (20%), lung (70%), brain (40%), and esophagus (60%). It is estimated that p53 mutations are the most frequent genetic event in human cancers, accounting for more than 50% of cases. One of the most striking features of the inactive mutant p53 protein is its increased stability (half‐life of several hours, compared to 20 min for wild‐type p53) and its accumulation in the nucleus of neoplastic cells. Therefore, positive immunostaining is indicative of abnormalities of the p53 gene and its product. Several studies have shown that p53 mutations are associated with short survival in colorectal cancer, but the use of p53 as a tumoral marker is still a matter of debate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
Lessons from hereditary colorectal cancer
Kinzler, K. W., & Vogelstein, B. (1996) · Cell · doi:10.1016/s0092-8674(00)81333-1 · Cited by 4,919
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Participation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 3,761
Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
Greenblatt, M. S., Bennett, W. P., Hollstein, M., & Harris, C. C. (1994) · PubMed · Cited by 3,463
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925
Mutations in the p53 gene occur in diverse human tumour types
Nigro, J. M., Baker, S. J., Preisinger, A. C., Jessup, J. M., Hosteller, R., Cleary, K., Signer, S. H., Davidson, N., Baylin, S., Devilee, P., et al. (1989) · Nature · doi:10.1038/342705a0 · Cited by 2,733
Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., & Giaccia, A. J. (1996) · Nature · doi:10.1038/379088a0 · Cited by 2,300
Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6
Yonish-Rouach, E., Resnftzky, D., Lotem, J., Sachs, L., Kimchi, A., & Oren, M. (1991) · Nature · doi:10.1038/352345a0 · Cited by 2,079
A role for sunlight in skin-cancer – UV-induced p53 mutations in squamous-cell carcinoma
Brash, D. E., Rudolph, J. A., Simon, J. A., Lin, A., McKenna, G. J., Baden, H. P., Halperin, A. J., & Pontén, J. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.22.10124 · Cited by 1,959
Wild-type p53 is a cell cycle checkpoint determinant following irradiation.
Kuerbitz, S. J., Plunkett, B. S., Walsh, W. V., & Kastan, M. B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.16.7491 · Cited by 1,837
Preferential Formation of Benzo[ a ]pyrene Adducts at Lung Cancer Mutational Hotspots in P53
Denissenko, M. F., Pao, A., Tang, M.-S., & Pfeifer, G. P. (1996) · Science · doi:10.1126/science.274.5286.430 · Cited by 1,650
Mutational hot spot in the p53 gene in human hepatocellular carcinomas
Hsu, I. C., Metcalf, R. A., Sun, T., Welsh, J. A., Wang, N. J., & Harris, C. C. (1991) · Nature · doi:10.1038/350427a0 · Cited by 1,534
Sunburn and p53 in the onset of skin cancer
Ziegler, A., Jonason, A. S., Leffellt, D. J., Simon, J. A., Sharma, H. W., Kimmelman, J., Remington, L., Jacks, T., & Brash, D. E. (1994) · Nature · doi:10.1038/372773a0 · Cited by 1,497
Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa
Bressac, B., Kew, M., Wands, J., & Ozturk, M. (1991) · Nature · doi:10.1038/350429a0 · Cited by 1,432
The complexity of p53 modulation: emerging patterns from divergent signals
Giaccia, A. J., & Kastan, M. B. (1998) · Genes & Development · doi:10.1101/gad.12.19.2973 · Cited by 1,314
p53: A Frequent Target for Genetic Abnormalities in Lung Cancer
Takahashi, T., Nau, M. M., Chiba, I., Birrer, M. J., Rosenberg, R. K., Vinocour, M., Levitt, M., Pass, H., Gazdar, A. F., & Minna, J. D. (1989) · Science · doi:10.1126/science.2554494 · Cited by 1,197
Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer.
Sparks, A. B., Morin, P. J., Vogelstein, B., & Kinzler, K. W. (1998) · PubMed · Cited by 1,008
The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage
Gong, J., Costanzo, A., Yang, H.-Q., Melino, G., Kaelin, W. G., Levrero, M., & Wang, J. Y. J. (1999) · Nature · doi:10.1038/21690 · Cited by 930
p14ARF links the tumour suppressors RB and p53
Bates, S., Phillips, A. C., Clark, P. A., Stott, F., Peters, G., Ludwig, R. L., & Vousden, K. H. (1998) · Nature · doi:10.1038/25867 · Cited by 918
Colorectal Cancer: Molecules and Populations
Potter, J. D. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.11.916 · Cited by 881
Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents.
Fritsche, M., Haessler, C., & Brandner, G. (1993) · PubMed · Cited by 747
p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage
Yuan, Z.-M., Shioya, H., Ishiko, T., Sun, X., Gu, J., Huang, Y., Lu, H., Kharbanda, S., Weichselbaum, R., & Kufe, D. (1999) · Nature · doi:10.1038/21704 · Cited by 578
TP53 tumor suppressor gene: A model for investigating human mutagenesis
Fromentel, C. C. D., & Soussi, T. (1992) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.2870040102 · Cited by 574
Self-citationp53 In tumour pathology: Can we trust immunohistochemistry?—revisited!
Hall, P. A., & Lane, D. P. (1994) · The Journal of Pathology · doi:10.1002/path.1711720103 · Cited by 561
Interaction of c-Abl and p73α and their collaboration to induce apoptosis
Agami, R., Blandino, G., Oren, M., & Shaul, Y. (1999) · Nature · doi:10.1038/21697 · Cited by 546
Linke, S. P., Clarkin, K. C., Di Leonardo, A., Tsou, A., & Wahl, G. M. (1996) · Genes & Development · doi:10.1101/gad.10.8.934 · Cited by 538
An immunochemical analysis of the human nuclear phosphoprotein p53
Vojtěšek, B., Bártek, J., Midgley, C. A., & Lane, D. P. (1992) · Journal of Immunological Methods · doi:10.1016/0022-1759(92)90122-a · Cited by 531
Fujiwara, T., Grimm, E. A., Mukhopadhyay, T., Zhang, W. W., Owen‐Schaub, L. B., & Roth, J. A. (1994) · PubMed · Cited by 515
Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline.
Fan, S., Smith, M. L., Rivet, D. J., Duba, D. E., Zhan, Q., Kohn, K. W., Fornace, A. J., & O'Connor, P. M. (1995) · PubMed · Cited by 490
A simple p53 functional assay for screening cell lines, blood, and tumors.
Flaman, J. M., Frebourg, T., Moreau, V, Charbonnier, F., Martin, C., Chappuis, P., Sappino, A. P., Limacher, I. M., Bron, L., & Benhattar, J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.9.3963 · Cited by 454
Fan, S., El‐Deiry, W. S., Bae, I., Freeman, J., Jondle, D., Bhatia, K. G., Fornace, A. J., MAGRATH, I. T., Kohn, K. W., & O'Connor, P. M. (1994) · PubMed · Cited by 454
Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer
Crawford, L. V., Pim, D. C., & Bulbrook, R. D. (1982) · International Journal of Cancer · doi:10.1002/ijc.2910300404 · Cited by 450
p53 mutation in hepatocellular carcinoma after aflatoxin exposure
Bressac, B., Puisieux, A., Kew, M., Volkmann, M., Bozcall, S., Bella Mura, J., de la Monte, S., Carlson, R., Blum, H., Wands, J., et al. (1991) · The Lancet · doi:10.1016/0140-6736(91)92236-u · Cited by 449
Sjogren, S., Inganas, M., Norberg, T., Lindgren, A., Nordgren, H., Holmberg, L., & Bergh, J. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.3-4.173 · Cited by 381
Multifactorial analysis of p53 alteration in human cancer: A review
Soussi, T., Legros, Y., Lubin, R., Ory, K., & Schlichtholz, B. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910570102 · Cited by 353
Self-citationAssociation of p53 mutations with short survival in colorectal cancer
Hamelin, R., Laurent-Puig, P., Olschwang, S., Jego, N., Asselain, B., Remvikos, Y., Girodet, J., Salmon, R. J., & Thomas, G. (1994) · Gastroenterology · doi:10.1016/s0016-5085(94)94217-x · Cited by 345
O'Connor, P. M., Jackman, J., Jondle, D., Bhatia, K. G., MAGRATH, I. T., & Kohn, K. W. (1993) · PubMed · Cited by 323
Serum p53 antibodies as early markers of lung cancer
Lubin, R., Zalcman, G., Bouchet, L., Trédaniel, J., Legros, Y., Cazals, D., Hirsch, A., & Soussi, T. (1995) · Nature Medicine · doi:10.1038/nm0795-701 · Cited by 318
Self-citationPaclitaxel Resistance in Non–Small-Cell Lung Cancer Associated With Beta-Tubulin Gene Mutations
Monzó, M., Rosell, R., Sánchez, J. J., Lee, J. S., O'Brate, A., González-Larriba, J. L., Alberola, V., Lorenzo, J. C., Núñez, L., Ro, J. Y., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.6.1786 · Cited by 306
Puisieux, A., Lim, S.-K., Groopman, J. D., & Öztürk, M. (1991) · PubMed · Cited by 298
The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2.
Eliopoulos, A. G., Kerr, R. S., Herod, J., Hodgkins, L., Krajewski, S., Reed, J. C., & Young, L. S. (1995) · PubMed · Cited by 296
Geographic Variation of p53 Mutational Profile in Nonmalignant Human Liver
Aguilar, F., Harris, C. C., Sun, T., Hollstein, M., & Cerutti, P. (1994) · Science · doi:10.1126/science.8191284 · Cited by 282
A Mutant p53 That Discriminates between p53-Responsive Genes Cannot Induce Apoptosis
Friedlander, P., Haupt, Y., Prives, C., & Oren, M. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4961 · Cited by 278
Differential Activation of Target Cellular Promoters by p53 Mutants with Impaired Apoptotic Function
Ludwig, R. L., Bates, S., & Vousden, K. H. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4952 · Cited by 275
p53 Mutations in non-small cell lung cancer in Japan: Association between mutations and smoking
(1992) · Lung Cancer · doi:10.1016/0169-5002(92)90041-h · Cited by 275
Soussi, T., Dehouche, K., & B�roud, C. (2000) · Human Mutation · doi:10.1002/(sici)1098-1004(200001)15:1<105::aid-humu19>3.0.co;2-g · Cited by 271
Self-citationAlternative genetic pathways in colorectal carcinogenesis
Olschwang, S., Hamelin, R., Laurent-Puig, P., Thuille, B., De Rycke, Y., Li, Y.-J., Muzeau, F., Girodet, J., Salmon, R.-J., & Thomas, G. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.22.12122 · Cited by 251
Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer
Bell, S. M., Scott, N., Cross, D., Sagar, P., Lewis, F. A., Blair, G. E., Taylor, G. R., Dixon, M. F., & Quirke, P. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)90835-z · Cited by 245
Screening patients for heterozygous p53 mutations using a functional assay in yeast
Ishioka, C., Frebourg, T., Yan, Y.-X., Vidal, M., Friend, S. H., Schmidt, S., & Iggo, R. (1993) · Nature Genetics · doi:10.1038/ng1093-124 · Cited by 243
p53 point mutation and survival in colorectal cancer patients.
Goh, H. S., Yao, J. T. D., & Smith, D. R. (1995) · PubMed · Cited by 234
Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array
Ahrendt, S. A., Halachmi, S., Chow, J. T., Wu, L., Halachmi, N., Yang, S. C., Wehage, S., Jen, J., & Sidransky, D. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.13.7382 · Cited by 230
Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma
Sun, X.-F., Carstensen, J. M., Stål, O., Wingren, S., Hatschek, T., Nordenskjöld, B., & Zhang, H. (1992) · The Lancet · doi:10.1016/0140-6736(92)92558-w · Cited by 223
Casey, G., Me, L., Jc, R., Sj, P., Arboleda, M. J., Shaughnessy, M., Karlan, B. Y., & Dj, S. (1996) · PubMed · Cited by 205
Xia, F., Wang, X., Wang, Y. H., Tsang, N. M., Yandell, D. W., Kelsey, K. T., & Liber, H. L. (1995) · PubMed · Cited by 197
p53 gene mutation: software and database
Beroud, C. (1996) · Nucleic Acids Research · doi:10.1093/nar/24.1.147 · Cited by 187
Ryan, K. M., & Vousden, K. H. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.7.3692 · Cited by 184
Spitz, F. R., Nguyen, D. N., Skibber, J. M., Meyn, R. E., Cristiano, R. J., & Roth, J. A. (1996) · PubMed · Cited by 179
Kaelin, W. G. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.7.594 · Cited by 173
p53 gene mutation: software and database
Béroud, C. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.1.200 · Cited by 153
Fisher, C., Gillett, C. E., Vojtěšek, B., Barnes, D. M., & Millis, R. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.4 · Cited by 145
Antibodies against p53 are associated with poor prognosis of colorectal cancer
Houbiers, J. G. A., van der Burg, S., van de Watering, L., Tollenaar, R., Brand, A., van de Velde, C., & Melief, C. J. M. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.386 · Cited by 141
Increased p53 protein content of colorectal tumours correlates with poor survival
Remvikos, Y., Tominaga, O., Hammel, P. R., Laurent‐Puig, P., Salmon, R. J., Dutrillaux, B., & Thomas, G. D. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.352 · Cited by 138
de Fromentel, C. C., Chandrasekaran, K., May, P., May-Levin, F., Mouriesse, H., & Lemerle, J. (1987) · International Journal of Cancer · doi:10.1002/ijc.2910390211 · Cited by 131
Trivers, G. E., Benedetti, V. M. D., Cawley, H., Caron, G., Harrington, A. M., Bennett, W. P., Jett, J. R., Colby, T. V., Tazelaar, H. D., Pairolero, P. C., et al. (1996) · PubMed · Cited by 128
Apoptotic death of tumor cells correlates with chemosensitivity, independent of p53 or bcl-2.
Wu, G. S., & El‐Deiry, W. S. (1996) · PubMed · Cited by 124
Børresen‐Dale, A., Lothe, R. A., Meling, G. I., Hainaut, P. L., Rognum, T. O., & Skovlund, E. (1998) · PubMed · Cited by 119
Dix, B. R., Robbins, P., Soong, R., Jenner, D. C., House, A. K., & Iacopetta, B. J. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910590606 · Cited by 115
Dumaz, N., Stary, A., Soussi, T., Daya–Grosjean, L., & Sarasin, A. R. (1994) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/0027-5107(94)90311-5 · Cited by 112
Self-citationPrognostic Value of p53 Genetic Changes in Colorectal Cancer
Kressner, U., Inganäs, M., Byding, S., Blikstad, I., Påhlman, L., Glimelius, B. L. G., & Lindmark, G. E. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.593 · Cited by 111
Clinical utility of the immunocytochemical detection of p53 protein in cytological specimens.
Dowell, S. P., Wilson, P., Derias, N. W., Lane, D. P., & Hall, P. A. (1994) · PubMed · Cited by 110
Regulation of Mutant p53 Temperature-sensitive DNA Binding
Friedlander, P. A., Legros, Y., Soussi, T., & Prives, C. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.41.25468 · Cited by 103
Self-citationEffects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent.
Forrester, K., Lupold, S. E., Ott, V. L., Chay, C. H., Band, V., Wang, X. W., & Harris, C. C. (1995) · PubMed · Cited by 100
Wu, G. S., & El‐Deiry, W. S. (1996) · Nature Medicine · doi:10.1038/nm0396-255a · Cited by 90
Tomizawa, Y., Kohno, T., Fujita, T., Kiyama, M., Saito, R., Noguchi, M., Matsuno, Y., Hirohashi, S., Yamaguchi, N., Nakajima, T., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1202384 · Cited by 89
Top, B., Mooi, W. J., Klaver, S. G., Boerrigter, L., Wisman, P., Elbers, H. R. J., Visser, S., & Rodenhuis, S. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910640203 · Cited by 79
Prognostic value of TP53 and K-ras-2 mutational analysis in stage III carcinoma of the colon
Pricolo, V. E., Finkelstein, S. D., Wu, T., Keller, G., Bakker, A., Swalsky, P. A., & Bland, K. I. (1996) · The American Journal of Surgery · doi:10.1016/s0002-9610(99)80071-3 · Cited by 78
Zalcman, G., Schlichtholz, B., Trédaniel, J., Urban, T., Lubin, R., Dubois, I., Milleron, B. J., Hirsch, A., & Soussi, T. (1998) · PubMed · Cited by 77
Self-citationp53 and Rb1 protein expression: are they prognostically useful in colorectal cancer?
Poller, D. N., Baxter, K. J., & Shepherd, N. A. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.14 · Cited by 72
Mutations of Ki-ras and p53 genes in colorectal cancer and their prognostic significance.
Morrin, M., Kelly, M. W., Barrett, E. J., & Delaney, P. (1994) · Gut · doi:10.1136/gut.35.11.1627 · Cited by 72
Humoral immune response against p53 protein in patients with colorectal carcinoma
Angelopoulou, K., Stratis, M., & Diamandis, E. P. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970106)70:1<46::aid-ijc7>3.0.co;2-6 · Cited by 62
Legros, Y., Lafon, C., & Soussi, T. (1994) · PubMed · Cited by 62
Self-citationThe p53 tumour suppressor gene: a model for molecular epidemiology of human cancer
Soussi, T. (1996) · Molecular Medicine Today · doi:10.1016/1357-4310(96)88756-9 · Cited by 55
Self-citationFujimoto, H., Sasaki, J.-I., Matsumoto, M., Suga, M., Ando, Y., Iggo, R. D., Tada, M., Saya, H., & Ando, M. (1998) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1998.tb03273.x · Cited by 54
Colorectal carcinoma in Hong Kong: epidemiology and genetic mutations
Yuen, S. T., Chung, L.-P., Leung, S., Luk, I. S. C., Chan, S., Ho, J., Ho, J., & Wyllie, A. H. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.605 · Cited by 43
Takagi, Y., Osada, H., Kuroishi, T., Mitsudomi, T., Kondo, M., Niimi, T., Saji, S., Gazdar, A. F., Takahashi, T., Minna, J. D., et al. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.258 · Cited by 33
Erratum: p73 is a human p53-related protein that can induce apoptosis
Jost, C. A., Marín, M. C., & Kaelin, W. G. (1999) · Nature · doi:10.1038/21710 · Cited by 7
Cited by
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335
The proteasome: a suitable antineoplastic target
Adams, J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1361 · Cited by 1,201
The molecular basis of retinal ganglion cell death in glaucoma
Almasieh, M., Wilson, A. M., Morquette, B., Cueva Vargas, J. L., & Di Polo, A. (2012) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2011.11.002 · Cited by 971
Molecular Predictors of Survival after Adjuvant Chemotherapy for Colon Cancer
Watanabe, T., Wu, T.-T., Catalano, P. J., Ueki, T., Satriano, R., Haller, D. G., Benson, A. B., & Hamilton, S. R. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104193441603 · Cited by 888
Mutant p53 drives invasion by promoting integrin recycling
Muller, P. A. J., Caswell, P. T., Doyle, B., Iwanicki, M. P., Tan, E. H., Karim, S., Lukashchuk, N., Gillespie, D. A., Ludwig, R. L., Gosselin, P., et al. (2009) · Cell · doi:10.1016/j.cell.2009.11.026 · Cited by 796
Metadata
- Authors
- SOUSSI, T.
- Venue
- Annals of the New York Academy of Sciences
- Publisher
- Wiley
- Published
- 2000-06
- Volume
- 910
- Issue
- 1
- Pages
- 121-139
- ISSN
- 0077-8923 (ISSN-L)
- 1749-6632
- OpenAlex
- W2084592288
- Cited by
- 332
- References
- 88
- FWCI
- 7.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.